2012
MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions
Chandhanayingyong C, Kim Y, Staples JR, Hahn C, Lee FY. MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions. Sarcoma 2012, 2012: 404810. PMID: 22577336, PMCID: PMC3345255, DOI: 10.1155/2012/404810.Peer-Reviewed Original ResearchBone sarcomasClinical trialsEwing's sarcomaLimb salvage surgeryCurrent therapeutic modalitiesRecent clinical trialsMAPK/ERK inhibitorsPromising therapeutic targetHigh-grade chondrosarcomaCytotoxic chemotherapeutic drugsMAPK/ERK signalingSalvage surgeryTherapy regimensClinical benefitMetastatic osteosarcomaInflammatory responseMAPK/ERKClinical dataLocal invasivenessTherapeutic modalitiesCurrent chemotherapyTherapeutic conceptsTherapeutic implicationsTherapeutic targetSarcoma
2004
Diagnostic value and limitations of fluorine-18 fluorodeoxyglucose positron emission tomography for cartilaginous tumors of bone.
Lee FY, Yu J, Chang SS, Fawwaz R, Parisien MV. Diagnostic value and limitations of fluorine-18 fluorodeoxyglucose positron emission tomography for cartilaginous tumors of bone. Journal Of Bone And Joint Surgery 2004, 86: 2677-85. PMID: 15590853, DOI: 10.2106/00004623-200412000-00014.Peer-Reviewed Original ResearchConceptsHigh-grade chondrosarcomaPositron emission tomographyStandardized uptake valueStandard uptake valueCartilage tumorsGlucose metabolismGrade IIUptake valueCartilaginous tumorsEmission tomographyTumor sizeHistopathologic gradePredictive valueFluorine-18 fluorodeoxyglucose positron emission tomographyLow-grade cartilage tumorsMaximal standard uptake valueMaximal standardized uptake valueFluorodeoxyglucose positron emission tomographyHigh standard uptake valueBenign bone tumorsHigh glucose metabolismNegative predictive valueSignificant differencesMalignant cartilaginous tumorsPositive predictive value